NanoViricides Receives Approval for Phase II Ebola Trial in DRC
NanoViricides has received regulatory approval from ACOREP in the Democratic Republic of Congo to begin a Phase II clinical trial for NV-387 oral gummies. The antiviral treatment targets the Bundibugyo … Read More